Liver cancer, the sixth most common cancer globally and the second-leading cause of cancer-related deaths, presents a critical public health threat. Diagnosis often occurs in advanced stages of the disease, aligning incidence with fatality rates. Given that established treatments, such as stereotactic body radiation therapy and transarterial radioembolization, face accessibility and affordability challenges, the emerging focus on cancer cell metabolism, particularly arginine (Arg) depletion, offers a promising research avenue. Arg-depleting enzymes show efficacy against Arg-auxotrophic cancers, including hepatocellular carcinoma (HCC). Thus, in this review, we explore the limitations of current therapies and highlight the potential of Arg depletion, emphasizing various Arg-hydrolyzing enzymes in clinical development.

中文翻译：

---

通过精氨酸消耗治疗肝癌

肝癌是全球第六大常见癌症，也是癌症相关死亡的第二大原因，对公共健康构成了严重威胁。诊断通常发生在疾病的晚期，使发病率与死亡率保持一致。鉴于立体定向全身放射治疗和经动脉放射栓塞等现有治疗方法面临可及性和负担能力的挑战，对癌细胞代谢，特别是精氨酸（Arg）消耗的新兴关注提供了一条有前途的研究途径。精氨酸消耗酶对精氨酸营养缺陷型癌症（包括肝细胞癌 (HCC)）具有功效。因此，在这篇综述中，我们探讨了当前疗法的局限性，并强调了精氨酸消耗的潜力，强调了临床开发中的各种精氨酸水解酶。